Leading Parkinson's Organizations Set Priorities for National Plan in Crucial Meeting

Leading Parkinson's Organizations Set Priorities for National Plan

On August 24, 2026, key leaders from major Parkinson's advocacy organizations like the American Parkinson Disease Association (APDA), The Michael J. Fox Foundation for Parkinson's Research (MJFF), and the Parkinson's Foundation convened in Washington to outline essential priorities for the National Plan to End Parkinson's disease. This meeting serves as the second instance for the federal Advisory Council tasked with developing this ambitious plan.

These organizations have submitted comprehensive recommendations in response to the National Institutes of Health's Request for Information (RFI), which was open for feedback beginning June 23 and concluded on August 22. The RFI invited individuals living with Parkinson's, as well as families, care partners, clinicians, and researchers to voice their concerns regarding the most pressing needs in research and care. Their feedback will be instrumental in shaping the upcoming Advisory Council discussions about Parkinson's disease research, care, and services.

As public interest shifts to addressing the growing concerns about Parkinson's and its societal impacts, recent legislative actions are also noteworthy. California's decision to phase out the herbicide paraquat—an ingredient known to elevate Parkinson's disease risk—reflects a broader national trend toward environmental safety. Similar bans have already been enforced in multiple states and over 70 countries.

In a joint statement, Anne Hubbard from APDA, Dan Feehan of MJFF, and Andi Lipstein Fristedt from the Parkinson's Foundation emphasized the significance of the RFI. They expressed that this was a pivotal moment for the Parkinson's community to articulate what a meaningful National Plan must include. The statement highlighted the importance of collaboration with the Department of Health and Human Services (HHS), the National Institutes of Health (NIH), and the National Institute of Neurological Disorders and Stroke (NINDS) to ensure that the voices of those affected by Parkinson’s disease are integral to the planning process.

The feedback from these organizations is centered around six achievable goals, the outcomes of which will ideally be realized by the year 2035:

1. Financial Relief: Aiming to alleviate the financial burden on families dealing with Parkinson's, the goal is to ensure affordable access to necessary services, better caregiver support, and policies that enhance economic security while mitigating the associated costs of the disease.

2. Improved Health Outcomes: The focus is on providing timely and coordinated care that prioritizes the health and well-being of individuals living with Parkinson's.

3. Disease Prevention: Efforts will be aimed at reducing environmental and toxic exposures that are linked to the onset of Parkinson's. This objective includes advancing therapeutic interventions that may prevent, alleviate symptoms, or halt the progression of the disease.

4. Enhanced Quality of Care: To ensure that individuals covered by federally funded healthcare programs receive higher quality and coordinated care that meets their needs throughout the course of the disease.

5. Research on Environmental Triggers: By increasing the understanding of environmental triggers linked to Parkinson's disease, this goal seeks to lead to more effective public policies aimed at reducing exposure to such risks.

6. Expanded Research Funding: Lastly, increasing federal research funding is crucial for unlocking deeper insights into the factors contributing to Parkinson's, ultimately facilitating the development of new therapies and potential cures.

As this movement gains momentum, all eyes will be on the Advisory Council meeting, which can be watched live on the HHS website from 10 a.m. to 4 p.m. ET on the designated date.

About the Organizations

The American Parkinson Disease Association (APDA) has been a pioneer in providing support and resources to those affected by Parkinson's since its inception in 1961. With more than $338 million raised for research and community support, the APDA remains committed to enhancing the lives of nearly one million Americans living with Parkinson's disease.

The Michael J. Fox Foundation (MJFF) is recognized globally for its extensive contributions to Parkinson's research, investing over $3 billion to expedite vital scientific advancements. Through innovative partnerships, MJFF plays a pivotal role in changing the landscape of Parkinson’s research and clinical trials.

The Parkinson's Foundation, operating since 1957, invests significantly in research and clinical care to improve the quality of life for Parkinson's patients while fostering community engagement and advocacy. With over $513 million allocated to date, the Foundation continues to focus on accelerating breakthroughs in understanding and treating Parkinson's disease.

In conclusion, as the nation turns its attention to actionable strategies against Parkinson's, the voices and experiences of those directly affected are paramount in shaping meaningful solutions to combat this chronic condition. The collaborative work anticipated at the Advisory Council meeting holds great promise for the future of Parkinson's disease management and research.